TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00705549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel I.V at the dose of 75mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 80mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 50mg every Monday, Wednesday and Friday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 50mg every Monday, Wednesday and Friday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexate
Description: Pemetrexate I.V 500mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexate
Description: Pemetrexate I.V 500mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexate
Description: Pemetrexate I.V 500mg/m2 on Day 1
Study: NCT01898559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to smoking only little cigars
Description: Participants smoke only little cigars for 15 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to smoking only little cigars
Description: Participants smoke only little cigars for 15 days.
Study: NCT00457457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-369,003
Description: UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
Study: NCT03636516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: extracorporeal shockwave lithotripsy apply

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: extracorporeal shockwave lithotripsy apply
Study: NCT04200352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: Oral tablets are 6, 9, and 12 mg.
Study: NCT00372593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: Given IV over 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: Given IV over 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV over 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV over 1-4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV over 1-4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1-4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone hydrochloride
Description: Given IV over 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone hydrochloride
Description: Given IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV over 1 hour
Study: NCT04236609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abluminus DES+ Sirolimus Eluting Stent System (SES)
Description: The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)
Description: The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA
Study: NCT04690452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training
Description: The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Compassion Cultivation Training
Description: The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
Study: NCT04506138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg D1, D22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection (Albumin Bound)
Description: Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 D1, D22
Study: NCT02702791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecoaching
Description: Pedeometer based goals and telecoaching support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.

Intervention type: OTHER
Group type: OTHER
Intervention: pulmonary rehabilitation
Description: Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
Study: NCT02212951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R U-500
Study: NCT01318980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] radiolabelled GSK2190915 solution
Description: Microtracer solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet administered to the proximal small bowel.
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Study: NCT04290832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO Intervention
Description: South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care
Study: NCT01318980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet administered to the distal small bowel.
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg enteric-coated tablet.
Description: Taken orally
Study: NCT04673396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norcantharidin Lipid Microsphere for Injection
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norcantharidin Lipid Microsphere for Injection
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norcantharidin Lipid Microsphere for Injection
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Demethylcantharidate Injection
Description: Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Study: NCT00612248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
Study: NCT03816293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
Study: NCT03603262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
Study: NCT01717924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peri-operative chemotherapy
Description: Usual treatment strategy for gastric adenocarcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery first
Description: strategy with a surgical procedure first, without the usual peri-operative chemotherapy
Study: NCT01651637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic surfactant (CHF5633)
Description: CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
Study: NCT01001325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral influenza vaccine, 2009-2010
Description: 0.5 mL intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5 mL intramuscular
Study: NCT02820493

Intervention type: DRUG
Group type: OTHER
Intervention: vedolizumab
Study: NCT01584440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-20
Description: AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-20
Description: AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-30
Description: AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-30
Description: AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
Study: NCT03212144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut Consumption
Description: Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
Study: NCT01185080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Nasal spray solution, intranasal, three times weekly for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray solution, intranasal, three times weekly for one month
Study: NCT00441597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatine 80mg, during 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatine 80mg, during 3 days
Study: NCT02393638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation and lecture
Description: Endoscopic sphincterotomy on simulator and lecture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Lecture
Study: NCT02868073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN (high dose) Oral Vaccine Tablet
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablets
Description: The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN (low dose) Oral Vaccine Tablet
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
Study: NCT02193074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made
Study: NCT03124563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention Condition
Description: Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
Study: NCT01185080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848 and placebo
Description: Nasal spray solution, intranasal, three times weekly for one month
Study: NCT03256916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic EBRT and Brachytherapy
Description: Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.

Intervention type: RADIATION
Group type: OTHER
Intervention: Pelvic EBRT and Brachytherapy
Description: Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
Study: NCT03196362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone + Metformin
Description: One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: One tablet of placebo will be given twice daily
Study: NCT04241419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Walking
Description: Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
Study: NCT04542018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a low FODMAP diet for 4 weeks
Description: low FODMAP diet for 4 weeks
Study: NCT04273035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: Oral Buccolam

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPAD
Description: Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
Study: NCT00802945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: NKTR-102 given on a q14 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: NKTR-102 given on a q21 day schedule
Study: NCT02145013

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy by either open, laparoscopic or robotic procedures

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy by either open, laparoscopic or robotic procedures
Study: NCT01562093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid nasal spray
Description: fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months